EUCTR2016-003100-30-DE进行中（未招募）1 期
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •-Patients with RRMS aged from 10 years to less than 18 years at study entry are eligible. Patients should meet the criteria of diagnosis of MS as defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS and the criteria of MS based on McDonald criteria 2010.
- •-Signed informed consent/assent obtained from patient and patient’s legal representative (parent or guardian) according to local regulations.
- •-Expanded Disability Status Scale (EDSS) score of 0.0 to 5.0 (inclusive) at screening.
- •-At least 2 recorded MS attacks and at least 1 MS attack (relapse) in the last year during treatment with a interferon-beta (IFNB) or glatiramer acetate (GA) after having been on that therapy for at least 6 months
- •-At least 1 of the following:
- •-=1 new or enlarging T2 hyperintense lesion or gadolinium enhancing lesion* while on that same prior therapy (IFNB or GA), OR
- •-Two or more relapses in the prior year, OR
- •-Tried at least 2 MS DMTs.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 65
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Any progressive or non-relapsing forms of MS.
- •-Conditions/situations such as:
- •-Impossibility to meet specific protocol requirements.
- •-Current participation in another interventional clinical study.
- •-Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
- •-Uncooperative patient or any condition that could make the patient potentially non-compliant tothe study procedures in the opinion of the Investigator.
- •-Mental condition rendering the patient or parent/guardian unable to understand the nature, scope, and possible consequences of the study.
- •-Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the patient at risk by participating in the study in the opinion of the Investigator.
- •-History of drug or alcohol abuse.
- •-History of known human immunodeficiency virus (HIV) positivity.
- •-Pregnant or breast-feeding female patients or those who plan to become pregnant during the study.
- •-Unwilling to agree to use a reliable and effective contraceptive method as defined for contraception in the Informed Consent form (ICF) when receiving a course of alemtuzumab treatment and for 4 months following that course of treatmenty (fertile patients only).
- •-Female patients who have commenced menstruating (ie, are of childbearing potential) and are unwilling or unable to be tested for pregnancy.
- •-Previous treatment with alemtuzumab
- •-Treatment with natalizumab, daclizumab, fingolimod, methotrexate, azathioprine, cyclosporine, or mycophenolate mofetil in the last 6 months prior to screening, or as determined by the treating physician to have residual immune suppression from these or other MS treatments.
- •- Treatment with teriflunomide in the last 12 months except if the patient underwent the recommended elimination procedure as per SmPC.
- •-Previous treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab, ocrelizumab, leflunomide, or any cytotoxic therapy.
- •-Previous treatment with any investigational medication (drug that has not been approved at any dose or for any indication). Use of an investigational medication that was subsequently licensed and nonstandard use of a licensed medication (eg, using a dose other than the dose that is stated in the licensed product labeling or using a licensed therapy for an alternative indication) is not exclusionary. Prior treatment with herbal medications or nutritional supplements is also permitted.
- •-Intolerance of pulsed corticosteroids, especially a history of steroid psychosis.
- •-History of malignancy
- •-Prior documented history of thrombocytopenia, or platelet count at screening < lower limits of normal (LLN).
- •-Any disability acquired from trauma or another illness that, in the opinion of the Investigator, could interfere with evaluation of disability due to MS.
- •-Patients with known Type 1 hypersensitivity or anaphylactic reactions to the active substan
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMTMedDRA version: 20.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2016-003100-30-FRGenzyme Corporation65
进行中（未招募）
1 期
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMTMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2016-003100-30-GRGenzyme Corporation65
进行中（未招募）
1 期
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMTMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2016-003100-30-BGGenzyme Corporation65
进行中（未招募）
1 期
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMTMedDRA version: 19.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2016-003100-30-ESGenzyme Corporation65
撤回
3 期
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)10012303Multiple sclerosisdemyelinating diseaseNL-OMON49585Sanofi-aventis1